What do systematic reviews say?

4 questions · 4 findings · 3 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 75%High 1 · 25%

Digital technology vs usual care

Exacerbations (number of people experiencing ≥ 1 exacerbations) · adolescents and adults with cystic fibrosis

Digital technology showed no clear difference in number of pulmonary exacerbations: number of participants… compared with usual care (moderate certainty).

1 finding from 1 review

Digital technology for early identification of exacerbations in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 1.07 [0.92, 1.25]
1 study · 267 participants
Moderate

Summary of findings: tobramycin for inhalation powder vs tobramycin

Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in pulmonary exacerbations: number of participants experiencing… compared with tobramycin (moderate certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.12 [0.86, 1.45]
1 study · 517 participants
Moderate

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.78 [0.55, 1.1]
1 study · 285 participants
High

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · children with cystic fibrosis and a new culture positive for P aeruginosa

Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with TNS plus oral placebo (moderate certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.75 [0.56, 1]
1 study · 221 participants
Moderate